ClinConnect ClinConnect Logo
Search / Trial NCT02472561

Verizon mHealth Solution for Patients With Peripheral Artery Disease (PAD)

Launched by DUKE UNIVERSITY · Jun 11, 2015

Trial Information

Current as of August 02, 2025

Completed

Keywords

Cardiology Vascular Peripheral Artery Disease Artery Mobile Health Exercise Pad

ClinConnect Summary

This is a single-center, randomized trial designed to examine the hypothesis that a lifestyle-based mHealth peripheral artery disease (PAD) prevention program will improve physical activity, fitness, important PAD risk factors and quality of life (QOL).

The investigators may enroll up to 55 men and women being evaluated for leg pain from Duke PAD cardiovascular clinics or after lower extremity angioplasty in the Duke catheterization laboratory. Of the 55 men and women volunteers who may be initially consented, the investigators anticipate a portion (potentially 20%) may drop out during the...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Adequate clinical stability has been achieved in the judgment of the investigator to allow participation in study assessments and the intervention
  • A history of stable intermittent claudication for \>2 months, and an ABI \<0.9 at rest
  • No contraindications to exercise training
  • All subjects will be on the recommended regimen of statin and antiplatelet therapy
  • Signed informed consent document indicating that the patient understands the purpose of and procedures required for the study and is willing to participate in the study
  • Exclusion Criteria:
  • Present or a past history of gangrene, impending limb loss or osteomyelitis
  • Severe peripheral neuropathy
  • Any condition other than PAD that limits walking for example arthritis or chronic obstructive pulmonary disease (COPD)
  • Unstable angina, history of significant left main disease or three vessel coronary artery disease (\>70% stenosis, unprotected by grafts) or recent myocardial infarction (less than eight weeks)
  • Chest pain during treadmill exercise which appears before the onset of claudication, or 2 mm ST depression during exercise regardless of the results of tests for myocardial ischemia
  • Refusal or inability to give informed consent or inability or unwillingness to comply with the study requirements.
  • Dementia that precludes ability to participate in and follow study protocols
  • Enrollment in a clinical trial not approved for co-enrollment.

About Duke University

Duke University, a leading academic and research institution located in Durham, North Carolina, is renowned for its commitment to advancing healthcare through innovative clinical research. With a strong emphasis on interdisciplinary collaboration, Duke conducts a wide array of clinical trials aimed at developing cutting-edge therapies and improving patient outcomes across various medical fields. The university's Clinical Research Institute provides comprehensive support for trial design, implementation, and regulatory compliance, ensuring that all research adheres to the highest ethical and scientific standards. Duke’s dedication to translating research findings into effective clinical practices underscores its role as a pivotal contributor to the global medical community.

Locations

Durham, North Carolina, United States

Patients applied

0 patients applied

Trial Officials

Manesh R Patel, MD

Principal Investigator

Duke University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials